REGENXBIO Inc.
RGNX
$6.72
$0.172.60%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -4.50% | -16.31% | 11.60% | -18.37% | -29.13% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -4.50% | -16.31% | 11.60% | -18.37% | -29.13% |
| Cost of Revenue | 8.18% | -5.32% | 2.23% | -5.59% | -319.62% |
| Gross Profit | -7.74% | -2.31% | 39.45% | -0.03% | 526.83% |
| SG&A Expenses | -18.11% | -15.86% | -20.44% | -19.19% | -13.35% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 605.93% | -83.18% | 11.54% | -203.03% | 100.79% |
| Total Operating Expenses | -11.93% | -8.09% | -15.85% | -9.27% | 0.98% |
| Operating Income | 14.68% | 4.44% | 23.35% | 6.64% | -19.76% |
| Income Before Tax | 18.81% | 3.67% | 26.47% | 5.02% | -5.11% |
| Income Tax Expenses | -- | -- | -- | -- | -253.49% |
| Earnings from Continuing Operations | 18.61% | 3.67% | 26.47% | 5.02% | -4.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 18.61% | 3.67% | 26.47% | 5.02% | -4.93% |
| EBIT | 14.68% | 4.44% | 23.35% | 6.64% | -19.76% |
| EBITDA | 15.26% | 4.08% | 24.30% | 7.09% | -21.07% |
| EPS Basic | 29.60% | 16.67% | 36.74% | 9.76% | -3.25% |
| Normalized Basic EPS | 25.39% | 16.67% | 36.74% | 12.75% | -11.27% |
| EPS Diluted | 29.60% | 16.79% | 36.75% | 9.76% | -2.96% |
| Normalized Diluted EPS | 25.39% | 16.67% | 36.74% | 12.75% | -11.27% |
| Average Basic Shares Outstanding | 15.61% | 15.60% | 16.24% | 5.25% | 1.63% |
| Average Diluted Shares Outstanding | 15.61% | 15.60% | 16.24% | 5.25% | 1.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
